Revolution Medicines Inc
$ 147.01
7.86%
14 Apr - close price
- Market Cap 27,011,033,000 USD
- Current Price $ 147.01
- High / Low $ 148.00 / 134.66
- Stock P/E N/A
- Book Value 8.28
- EPS -5.95
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.58 %
- 52 Week High 148.00
- 52 Week Low 34.00
About
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Analyst Target Price
$133.70
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-24 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-26 | 2023-11-06 | 2023-08-08 | 2023-05-08 |
| Reported EPS | -1.86 | -1.61 | -1.31 | -1.13 | -1.12 | -0.94 | -0.81 | -0.7 | -1.14 | -0.99 | -0.92 | -0.72 |
| Estimated EPS | -1.58 | -1.41 | -1.12 | -0.75 | -0.9645 | -0.89 | -0.77 | -0.75 | -0.88 | -1.01 | -0.82 | -0.81 |
| Surprise | -0.28 | -0.2 | -0.19 | -0.38 | -0.1555 | -0.05 | -0.04 | 0.05 | -0.26 | 0.02 | -0.1 | 0.09 |
| Surprise Percentage | -17.7215% | -14.1844% | -16.9643% | -50.6667% | -16.1223% | -5.618% | -5.1948% | 6.6667% | -29.5455% | 1.9802% | -12.1951% | 11.1111% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.78 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RVMD
2026-04-13 20:40:14
Revolution Medicines (RVMD) stock surged 39% following the announcement of successful Phase 3 clinical trial results for its pancreatic cancer treatment. The positive outcome of the trial has significantly boosted investor confidence in the biotechnology company. This development marks a major milestone for Revolution Medicines and its efforts in oncology.
2026-04-13 15:47:00
Revolution Medicines announced "unprecedented" survival results for its drug daraxonrasib in a pivotal Phase 3 pancreatic cancer trial, with patients living nearly six months longer than those on standard chemotherapy. The company plans to seek speedy regulatory approval through a new FDA pilot program and will present the full data at the upcoming ASCO meeting. Daraxonrasib, a RAS inhibitor, demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival for patients with previously treated metastatic pancreatic ductal adenocarcinoma.
2026-04-13 13:39:00
Jim Cramer and David Faber discuss Revolution Medicines' stock in this "Cramer's Mad Dash" segment. The article provides a timestamped video of their conversation, indicating analysis of Revolution Medicines (RVMD).
2026-04-13 11:39:00
Revolution Medicines announced positive Phase 3 trial results for its drug daraxonrasib in metastatic pancreatic cancer, showing a significant improvement in overall survival (13.2 months vs. 6.7 months for chemotherapy). The company plans global regulatory submissions, including a U.S. New Drug Application, and will present full data at ASCO 2026. This news led to a substantial increase in Revolution Medicines' stock value.
2026-04-13 11:09:52
Goldman Sachs shares fell despite beating earnings estimates, due to lower fixed income, currencies, and commodities trading. Revolution Medicines surged over 37% after its pancreatic cancer drug succeeded in a phase 3 trial. Fastenal saw a 4% dip after its first-quarter earnings met expectations, while other homebuilders like Toll Brothers and Pultegroup rose on analyst upgrades.
2026-04-12 09:48:00
This article analyzes Revolution Medicines Inc (NASDAQ: RVMD) using AI models, identifying weak near-term sentiment but long-term strength. It highlights a significant short setup with a 14.9% downside target versus a 0.3% risk. The analysis provides specific institutional trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging.
